A Systematic Literature Review of the Human Papillomavirus Prevalence in Locally and Regionally Advanced and Recurrent/metastatic Head and Neck Cancers Through the Last Decade: The "ALARM" Study

Overview

Journal Cancer Med

Specialty Oncology

Date 2024 Jan 22

PMID 38247106

Authors

Sofia Agelaki

Ioannis Boukovinas

Ilias Athanasiadis

Georgios Trimis

Ioannis Dimitriadis

Lazaros Poughias

Edith Morais

Ugne Sabale

Goran Bencina

Charalampos Athanasopoulos

Affiliations

Soon will be listed here.

Abstract

Aims: The aim of this systematic literature review was to provide updated information on human papillomavirus (HPV) prevalence in locally and regionally advanced (LA) and recurrent/metastatic (RM) head and neck cancer (HNC) worldwide.

Methods: Electronic searches were conducted on clinicaltrials.gov, MEDLINE/PubMed, Embase, and ASCO/ESMO journals of congresses for interventional studies (IS; Phase I-III trials) as well as MEDLINE and Embase for non-interventional studies (NIS) of LA/RM HNC published between January 01, 2010 and December 31, 2020. Criteria for study selection included: availability of HPV prevalence data for LA/RM HNC patients, patient enrollment from January 01, 2010 onward, and oropharyngeal cancer (OPC) included among HNC types. HPV prevalence per study was calculated as proportion of HPV+ over total number of enrolled patients. For overall HPV prevalence across studies, mean of reported HPV prevalence rates across studies and pooled estimate (sum of all HPV+ patients over sum of all patients enrolled) were assessed.

Results: Eighty-one studies (62 IS; 19 NIS) were included, representing 9607 LA/RM HNC cases, with an overall mean (pooled) HPV prevalence of 32.6% (25.1%). HPV prevalence was 44.7% (44.0%) in LA and 24.3% (18.6%) in RM. Among 2714 LA/RM OPC patients from 52 studies with available data, mean (pooled) value was 55.8% (50.7%). The majority of data were derived from Northern America and Europe, with overall HPV prevalence of 46.0% (42.1%) and 24.7% (25.3%) across studies conducted exclusively in these geographic regions, respectively (Northern Europe: 31.9% [63.1%]). A "p16-based" assay was the most frequently reported HPV detection methodology (58.0%).

Conclusion: Over the last decade, at least one quarter of LA/RM HNC and half of OPC cases studied in IS and NIS were HPV+. This alarming burden is consistent with a potential implication of HPV in the pathogenesis of at least a subgroup of HNC, underscoring the relevance of HPV testing and prophylaxis to HNC prevention and management.

Citing Articles

Hydrogels with Essential Oils: Recent Advances in Designs and Applications.

Chelu M Gels. 2024; 10(10).

PMID: 39451288 PMC: 11508064. DOI: 10.3390/gels10100636.

A systematic literature review of the human papillomavirus prevalence in locally and regionally advanced and recurrent/metastatic head and neck cancers through the last decade: The "ALARM" study.

Agelaki S, Boukovinas I, Athanasiadis I, Trimis G, Dimitriadis I, Poughias L Cancer Med. 2024; 13(3):e6916.

PMID: 38247106 PMC: 10905345. DOI: 10.1002/cam4.6916.

References

Karam S, Reddy K, Blatchford P, Waxweiler T, DeLouize A, Oweida A . Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. Clin Cancer Res. 2018; 24(20):4949-4959. PMC: 6873707. DOI: 10.1158/1078-0432.CCR-18-0467. View

Chiu J, Chan K, Chen E, Siu L, Abdul Razak A . Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT). Invest New Drugs. 2015; 33(4):895-900. DOI: 10.1007/s10637-015-0245-3. View

Fietkau R, Hecht M, Hofner B, Lubgan D, Iro H, Gefeller O . Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial. Radiother Oncol. 2020; 144:209-217. DOI: 10.1016/j.radonc.2020.01.016. View

Reuschenbach M, Tinhofer I, Wittekindt C, Wagner S, Klussmann J . A systematic review of the HPV-attributable fraction of oropharyngeal squamous cell carcinomas in Germany. Cancer Med. 2019; 8(4):1908-1918. PMC: 6488137. DOI: 10.1002/cam4.2039. View

Kreimer A, Clifford G, Boyle P, Franceschi S . Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14(2):467-75. DOI: 10.1158/1055-9965.EPI-04-0551. View

Bussu F, Sali M, Gallus R, Vellone V, Zannoni G, Autorino R . HPV infection in squamous cell carcinomas arising from different mucosal sites of the head and neck region. Is p16 immunohistochemistry a reliable surrogate marker?. Br J Cancer. 2013; 108(5):1157-62. PMC: 3619072. DOI: 10.1038/bjc.2013.55. View

Zandberg D, Algazi A, Jimeno A, Good J, Fayette J, Bouganim N . Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2018; 107:142-152. DOI: 10.1016/j.ejca.2018.11.015. View

Faraji F, Eisele D, Fakhry C . Emerging insights into recurrent and metastatic human papillomavirus-related oropharyngeal squamous cell carcinoma. Laryngoscope Investig Otolaryngol. 2017; 2(1):10-18. PMC: 5510283. DOI: 10.1002/lio2.37. View

Hoffmann C, Calugaru V, Borcoman E, Moreno V, Calvo E, Liem X . Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx. Eur J Cancer. 2021; 146:135-144. DOI: 10.1016/j.ejca.2021.01.007. View

10.

Bossi P, Bergamini C, Miceli R, Cova A, Orlandi E, Resteghini C . Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016; 96(5):959-966. DOI: 10.1016/j.ijrobp.2016.08.047. View

11.

Shewale J, Gillison M . Dynamic factors affecting HPV-attributable fraction for head and neck cancers. Curr Opin Virol. 2019; 39:33-40. DOI: 10.1016/j.coviro.2019.07.008. View

12.

Kim K, Lewis Jr J, Chen Z . Current status of clinical testing for human papillomavirus in oropharyngeal squamous cell carcinoma. J Pathol Clin Res. 2018; 4(4):213-226. PMC: 6174616. DOI: 10.1002/cjp2.111. View

13.

Day T, Shirai K, OBrien P, Matheus M, Godwin K, Sood A . Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial. Clin Cancer Res. 2018; 25(4):1156-1164. PMC: 6377824. DOI: 10.1158/1078-0432.CCR-18-2024. View

14.

Rodriguez C, Wu Q, Voutsinas J, Fromm J, Jiang X, Pillarisetty V . A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. Clin Cancer Res. 2019; 26(4):837-845. DOI: 10.1158/1078-0432.CCR-19-2214. View

15.

Martens R, Koopman T, Noij D, Pfaehler E, Ubelhor C, Sharma S . Predictive value of quantitative F-FDG-PET radiomics analysis in patients with head and neck squamous cell carcinoma. EJNMMI Res. 2020; 10(1):102. PMC: 7477048. DOI: 10.1186/s13550-020-00686-2. View

16.

De Vincenzo R, Conte C, Ricci C, Scambia G, Capelli G . Long-term efficacy and safety of human papillomavirus vaccination. Int J Womens Health. 2015; 6:999-1010. PMC: 4262378. DOI: 10.2147/IJWH.S50365. View

17.

Tao Y, Biau J, Sun X, Sire C, Martin L, Alfonsi M . Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol. 2022; 34(1):101-110. DOI: 10.1016/j.annonc.2022.10.006. View

18.

de Sanjose S, Serrano B, Tous S, Alejo M, Lloveras B, Quiros B . Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectr. 2019; 2(4):pky045. PMC: 6649711. DOI: 10.1093/jncics/pky045. View

19.

. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2008; 90:1-636. PMC: 4781057. View

20.

Termine N, Panzarella V, Falaschini S, Russo A, Matranga D, Lo Muzio L . HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). Ann Oncol. 2008; 19(10):1681-90. DOI: 10.1093/annonc/mdn372. View